Physician profile
John J Thoppil
NPI 1336138064
$25,139.61
in general payments reported to CMS, 2019-2025
50 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $2,161 · 2021: $1,180 · 2022: $2,469 · 2023: $15K · 2024: $1,234 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $3,645 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,000.00 |
| Food and Beverage | $3,645.27 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $14,450.82 | 2020-2025 | Slynd |
| Therapeuticsmd, INC. | $2,024.94 | 2019-2022 | |
| Shield Therapeutics INC | $1,712.08 | 2022-2024 | Accrufer |
| Abbvie INC. | $993.63 | 2019-2025 | |
| Hologic Sales and Service, LLC | $853.00 | 2019-2025 | Acessa Provu System, Aptima, Novasure |
| Davol INC. | $640.34 | 2023-2024 | Phasix Mesh, Arista Ah Flexitip |
| Mayne Pharma Commercial LLC | $549.07 | 2022-2025 | |
| Astellas Pharma US INC | $391.55 | 2019-2025 | Veozah |
| Evofem Biosciences, INC. | $372.09 | 2021-2024 | Phexxi |
| Dysis Medical, INC. | $361.68 | 2019-2021 | |
| Lupin INC. | $346.68 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $327.05 | 2019-2021 | |
| Novo Nordisk INC | $300.15 | 2025 | Wegovy, Ozempic |
| Alexion Pharmaceuticals, INC. | $246.30 | 2023-2024 | Ultomiris |
| Coopersurgical, INC. | $154.70 | 2019-2023 | Summit Doppler |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $153.14 | 2024-2025 | |
| Exact Sciences Corporation | $123.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Avion Pharmaceuticals | $115.14 | 2019-2021 | |
| Biogen, INC. | $90.25 | 2025 | Zurzuvae |
| Avanos Medical | $88.16 | 2019-2023 | On-Q* Pump and Accessories |
| Bausch Health US, LLC | $55.18 | 2022-2023 | Wellbutrin, Aplenzin |
| Kowa Pharmaceuticals America, INC. | $53.31 | 2022-2023 | Seglentis |
| Gynesonics, INC. | $52.21 | 2021 | |
| Allergan, INC. | $50.82 | 2019-2020 | |
| Myriad Women'S Health, INC. | $49.14 | 2023 | Myrisk |
| Organon LLC | $44.90 | 2022-2025 | Nexplanon |
| Meditrina | $44.05 | 2021 | |
| Baxter Healthcare | $41.87 | 2019-2020 | |
| Duchesnay USA Incorporated | $34.47 | 2019 | |
| Octapharma USA, INC. | $34.01 | 2025 | Fibryga |
| Agile Therapeutics, INC. | $33.38 | 2021 | |
| Millicent US INC | $31.92 | 2024-2025 | Intrarosa, Femlyv |
| Acessa Health INC. | $30.12 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $27.53 | 2023 | Exparel |
| Mission Pharmacal Company | $26.89 | 2021-2023 | Citranatal |
| Smith+Nephew, INC. | $24.93 | 2023 | Pico 7 |
| Glaxosmithkline, LLC. | $24.41 | 2023 | Shingrix |
| Kaleo, INC. | $19.35 | 2022 | |
| Becton, Dickinson and Company | $19.34 | 2024 | Arista Ah Flexitip |
| Lilly USA, LLC | $18.47 | 2024 | Zepbound |
| Innovation Technologies INC | $16.47 | 2025 | Irrisept |
| Medicem INC. | $15.77 | 2021 | |
| Myovant Sciences INC. | $15.45 | 2022 | |
| Roche Diagnostics Corporation | $15.12 | 2019 | |
| Minerva Surgical, INC | $13.96 | 2019 | |
| Scynexis, INC. | $13.90 | 2022 | |
| Currax Pharmaceuticals LLC | $13.53 | 2023 | Contrave |
| Aspira Women'S Health INC | $12.76 | 2024 | Ova1 |
| Channel Medsystems, INC. | $11.70 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thoppil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.